Loading
Among the HER2CLIMB patients with brain metastases, tucatinib doubled the intracranial response rate, cut the risk of intracranial progression or death by about two thirds and lengthened survival.
Exploratory analysis of the 291 HER2CLIMB patients with brain metastases at baseline, including 174 with active lesions.
Risk of intracranial progression or death was reduced by 68 percent with tucatinib, median central nervous system progression-free survival was 9.9 versus 4.2 months, intracranial response was 47.3 versus 20.0 percent, and median overall survival was 18.1 versus 12.0 months.
This analysis is the evidence base for treating active HER2-positive brain metastases with a systemic regimen, sometimes deferring radiotherapy, and for tucatinib's brain-specific labelling.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab.
Shares Tucatinib, Trastuzumab, Capecitabine.
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares Systemic-first management of HER2-positive brain metastases, HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares Tucatinib, Trastuzumab, Capecitabine.
Shares Trastuzumab, Journal of Clinical Oncology.